Skip to main
XAIR

XAIR Stock Forecast & Price Target

XAIR Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Beyond Air Inc. is well-positioned for growth, supported by a completed $5.0 million capital raise that enhances balance sheet flexibility ahead of the anticipated FDA approval of its second-generation LungFit system, which is crucial for its U.S. commercial strategy. The company's focus on enhancing its device platform and expanding international distribution across approximately 40 countries within nine months suggests strong potential for global market penetration, particularly in the treatment of pulmonary conditions and infectious diseases. Additionally, positive preliminary data from its intratumoral ultra-high concentration Nitric Oxide (UNO) therapy highlights a favorable safety profile and early signals of clinical activity, reinforcing the company’s innovative approach to potential oncology applications.

Bears say

Beyond Air Inc faces significant challenges with the launch of its first-generation LungFit system, highlighting issues such as regulatory delays and lack of inter-hospital transport capabilities, which hinder its market entry and adoption. Furthermore, the company's strategic shift to position its UNO device as an immunotherapy enhancer rather than a standalone tool may reflect underlying concerns about its standalone efficacy and market viability. These factors, combined with the effects of pandemic-driven changes on the ventilation landscape, contribute to a negative outlook on the company's financial performance and growth potential.

XAIR has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beyond Air Inc (XAIR) Forecast

Analysts have given XAIR a Strong Buy based on their latest research and market trends.

According to 1 analysts, XAIR has a Strong Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beyond Air Inc (XAIR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.